<DOC>
	<DOCNO>NCT02199509</DOCNO>
	<brief_summary>Background : - People dystonia control muscle contraction . This disorder affect different body area . When affect face , tongue , jaw , call oromandibular dystonia ( OMD ) cranial dystonia ( CD ) . Researchers want find drug treat seizures may help people kind dystonia . Objective : - To see levetiracetam improve symptom jaw face dystonia . Eligibility : - Adults age 18 70 OMD CD . Design : - Participants screen medical history physical exam . Researchers test severe dystonia . - Participants blood drawn needle arm . - Participants assign take either levetiracetam placebo . - Phase 1 : - Participants start one 500-mg tablet twice daily . The dose increase 500 mg every 3 day . The maximum dose 4000 mg day 3 week . Participants tolerate take high dose . - Participants return study visit week 3 6 . They ask health , side effect , symptom depression . They neurological examination test dystonia . - After week 6 visit , participant taper stop study drug 1 week . - Phase 2 begin one week later . Participants repeat phase 1 , drug . - After phase 2 , participant return usual clinic . They tell stop take drug . They follow-up phone call 2 week later .</brief_summary>
	<brief_title>Efficacy Levetiracetam Oromandibular Cranial Dystonia</brief_title>
	<detailed_description>Objectives : -- To determine efficacy levetiracetam ( LVT ) reduce symptoms subject oromandibular dystonia ( OMD ) cranial dystonia ( CD ) assess dystonia rating scale report adverse event study . Sample Size Population : -- We plan recruit 10 subject either primary OMD CD Movement Disorders Botulinum Toxin ( BoNT ) Clinics HMCS . Design : -- This randomized , double-blind placebo control cross-over study . All subject receive baseline evaluation dystonia assess eye , mouth , speech swallow subscores Burke-Fahn-Marsden ( BFM ) dystonia scale , eye upper low face , jaw , tongue subscores Global Dystonia Severity ( GDS ) rating scale . They randomize two group . Either LVT placebo titration schedule total daily dose 4000 mg prescribe six week . After week 6 , subject undergo taper wash-out period ( one week taper one week washout ) . The two group switch opposite intervention ( LVT placebo ) , follow titration taper pattern . We evaluate group week 3 , 6 , 11 14 use scale . This study require six outpatient visit NIH CC ; total duration study 15 week . Outcome measurement : Primary outcome : The percent change sum eye , mouth , speech swallow subscores BFM dystonia scale week 6 14 comparing baseline . Secondary outcome : The percent change sum eye , mouth , speech swallow subscores BFM dystonia scale week 3 11 sum eye upper face , low face jaw tongue subscores GDS rating scale week 3 , 6 , 11 14 compare baseline adverse event .</detailed_description>
	<mesh_term>Dystonia</mesh_term>
	<mesh_term>Dystonic Disorders</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>INCLUSION CRITERIA FOR THE PARTICIPANTS : 1 . Be least 18 year age less equal 80 year age . 2 . Must able provide consent . 3 . Primary OMD CD diagnose movement disorder specialist . 4 . No history receive LVT . 5 . If subject use medication dystonia anticholinergic , baclofen , benzodiazepine tetrabenazine , dosage must stay start 4 week participation throughout duration study . Subjects also prohibit start new medication dystonia . 6 . If subject inject BoNT , late dose must inject least 12 week participation study . 7 . Subject willing receive BoNT injection entire study . EXCLUSION CRITERIA FOR THE PARTICIPANTS : 1 . Psychiatric comorbidities depression , psychosis phobic disorder . 2 . Has history brain tumor , stroke , document history peripheral trauma mouth , jaw face within year onset dystonia , epilepsy seizure . 3 . Secondary OMD CD . 4 . Postural instability , frequent fall , severe vertigo dizziness severe ataxia . 5 . Inability take medication via oral route due severe degree OMD . 6 . An estimated creatinine clearance ( eCrCL ) less 50 mL/min . 7 . Pregnant , lactate plan become pregnant 6 month . Women able get pregnant must willing use effective method contraception time enrollment 3 month last dose study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Levetiracetam</keyword>
	<keyword>Cranial Dystonia</keyword>
	<keyword>Oromandibular Dystonia</keyword>
</DOC>